Lucentis, Avastin, and the role of licensing
Two drugs for treating age-related macular degeneration (AMD), a disease that can lead to important loss of vision, have recently been much in the news. The drugs are Lucentis (generic name ranibizumab), which is expensive and is licensed for the treatment of AMD, and Avastin (generic name bevacizumab), which is much cheaper, but not licensed for the treatment of AMD. Both drugs are inhibitors of vascular endothelial growth factor A. In other words, they have the same mechanism of action. … Continue reading